By ONN Staff

Kilan C. Ashad-Bishop details how chronic heat impacts oncology treatment adherence, hydration, and financial security for patients.

FDA approves capivasertib with abiraterone for PTEN-deficient mAPMN/S prostate cancer, requiring specific nursing education on intermittent dosing.

Explore how ctDNA and AI algorithms are optimizing bladder cancer treatment and managing BCG shortages, as discussed at OneOncology APP Symposium.

Larry Bilbrey of Tennessee Oncology explains how AI scribes reduce documentation burden and burnout while improving patient-provider engagement.

FDA approved belzutifan plus pembrolizumab for adjuvant clear cell renal cell carcinoma at high risk of recurrence following nephrectomy.

Michael Adashek, DO, explores why oncology providers must prioritize cascade testing to protect patients’ families from hereditary cancer risks.

Celebrating 25 years, Dana-Farber’s Cantor Center integrates oncology nursing science into clinical practice to improve patient quality of life.

New research finds extreme heat causes cancer patients to skip appointments and reduce activity, highlighting a need for clinical heat-risk planning.

Experts discuss how body image, fatigue, and shifting relationship roles impact sexual health and intimacy for patients undergoing cancer care.

Dr. Loren Rourke discusses how GLP-1s may impact breast cancer risk by reducing adipose tissue-derived estrogen and chronic metabolic inflammation.

Olympic legend Shannon Miller reflects on her 15-year ovarian cancer journey and why oncology nurses are the key to breaking patient silence.

UC Irvine researchers link ADCs to severe neutropenia, urging oncology nurses to prioritize proactive monitoring and care for at-risk patients.

Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC.

Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.

ASCO 2026 research highlights GLP-1 medications as a potential breast cancer prevention tool, showing a 30% risk reduction in retrospective analysis.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

Oncology nurses play a vital role in managing cognitive and metabolic toxicities during long-term lorlatinib therapy for ALK+ NSCLC.

The FDA approved Cavhanza, a nilotinib ODT that allows co-administration with PPIs and H2RAs, easing dosing and administration for Ph+ CML patients.

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.

ASCO 2026: Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab monotherapy.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects.

The FDA approved durvalumab plus BCG for high-risk NMIBC based on significant disease-free survival gains in the POTOMAC trial.